Could an Everyday Mineral Become a New Weapon Against Cancer? Scientists Are Exploring the Surprising Role of Copper

For decades, copper has been recognized as an essential mineral for human health. Today, researchers are investigating whether it could also become an unexpected ally in the fight against cancer.

When most people think of copper, they picture electrical wires, coins, or plumbing pipes. Few realize that this trace element is also vital for the human body. Copper helps cells produce energy, supports the function of several enzymes, and contributes to normal cellular activity.

Surprisingly, this same mineral may reveal one of cancer’s weaknesses.

Scientists have recently described a form of regulated cell death known as cuproptosis. It occurs when excessive amounts of copper accumulate inside a cell. Instead of helping the cell function, the excess copper disrupts key proteins involved in mitochondrial energy production. This produces severe cellular stress, causes the metabolic machinery to fail, and eventually leads to cell death. The review identifies cuproptosis as an emerging mechanism with potential therapeutic relevance in breast cancer.

This concept is especially interesting because many tumors require large amounts of energy to sustain rapid growth. Their intense metabolic activity may therefore become a point of vulnerability. In simple terms, the same machinery that allows a cancer cell to survive could potentially be used to destroy it.

Researchers are already exploring ways to take advantage of this process. Some experimental nanomedicines are designed to deliver copper directly into tumor cells, raising intracellular copper to toxic levels while attempting to limit damage to healthy tissues. In preclinical models of breast cancer, these strategies have shown antitumor activity.

A protein called FDX1 appears to play an important role in this process because it helps regulate copper-related mitochondrial activity. Tumors with specific metabolic characteristics may be more sensitive to cuproptosis, although the best biomarkers for identifying these patients are still under investigation.

It is important to clarify what these findings do not mean. Taking copper supplements or increasing dietary copper has not been shown to treat cancer. The research involves highly controlled methods designed to alter copper levels specifically inside tumor cells. These approaches are still experimental and are not part of standard cancer treatment.

Cuproptosis reflects a broader change in oncology. Rather than focusing only on damaging DNA or stopping cell division, researchers are increasingly studying the metabolic dependencies that cancer cells need to survive. Those dependencies may eventually become new therapeutic targets.

The evidence remains preclinical, and many questions are still unresolved, including which tumors are most susceptible, how to deliver copper safely, and whether this strategy can improve outcomes in patients. Even so, cuproptosis offers a compelling example of how a normal biological requirement can become a therapeutic weakness. The same copper that supports cellular life may, under the right conditions, help trigger the death of a cancer cell.